Ertaczo
Temporary Tattoos May Put You at Risk »
"Spring break is on the way, or maybe summer vacation. Time to pack your swim suit, hit the beach, and perhaps indulge in a little harmless fun. What about getting a temporary tattoo to mark the occasion? Who could it hurt to get a temporary tatto"...
Ertaczo
CLINICAL PHARMACOLOGY
Pharmacokinetics
In a multiple dose pharmacokinetic study that included 5 male patients with interdigital tinea pedis (range of diseased area, 42 - 140 cm²; mean, 93 cm²), ERTACZO® (sertaconazole nitrate) Cream, 2%, was topically applied every 12 hours for a total of 13 doses to the diseased skin (0.5 grams sertaconazole nitrate per 100 cm²). Sertaconazole concentrations in plasma measured by serial blood sampling for 72 hours after the thirteenth dose were below the limit of quantitation (2.5 ng/mL) of the analytical method used.
Microbiology
Sertaconazole is an antifungal that belongs to the imidazole class of antifungals. While the exact mechanism of action of this class of antifungals is not known, it is believed that they act primarily by inhibiting the cytochrome P450-dependent synthesis of ergosterol. Ergosterol is a key component of the cell membrane of fungi, and lack of this component leads to fungal cell injury primarily by leakage of key constituents in the cytoplasm from the cell.
Activity In Vivo
Sertaconazole nitrate has been shown to be active against isolates of the fol-lowing microorganisms in clinical infections as described in the INDICATIONS AND USAGE section:
Trichophyton rubrum
Trichophyton mentagrophytes
Epidermophyton floccosum
Clinical studies
In two randomized, double-blind, clinical trials, patients 12 years and older with interdigital tinea pedis applied either ERTACZO® (sertaconazole nitrate) Cream, 2%, or vehicle, twice daily for four weeks.Patients with moccasin-type (plantar) tinea pedis and/or onychomycosis were excluded from the study. Two weeks after completion of therapy (six weeks after beginning therapy), patients were evaluated for signs and symptoms related to interdigital tinea pedis.
Treatment outcomes are summarized in the table below.
Treatment Outcomes as Percent (%) of Total Subjects
| Study 1 | Study 2 | |||
| Sertaconazole | Vehicle | Sertaconazole | Vehicle | |
| Complete Cure* (Primary Efficacy Variable) |
13/99 (13.1%) | 3/92 (3.3 %) | 28/103 (27.2%) | 5/103 (4.9%) |
| Effective Treatment** | 32/99 (32.3%) | 11/92 (12.0%) | 52/103 (50.5%) | 16/103 (15.5%) |
| Mycological Cure*** | 49/99 (49.5%) | 18/92 (19.6%) | 71/103 (68.9%) | 20/103 (19.4%) |
| *Complete Cure - Patients who had complete
clearing of signs and symptoms and Mycological Cure. ** Effective Treatment - Patients who had minimal residual signs and symptoms of interdigital tinea pedis and Mycological Cure. *** Mycological Cure - Patients who had both negative microscopic KOH preparation and a negative fungal culture. |
||||
In clinical trials, complete cure in sertaconazole treated patients was achieved in 32 of 160 (20%) patients with Trichophyton rubrum, in 7 of 28 (25%) patients with Trichophyton menta-grophytes and in 2 of 13 (15%) patients with Epidermophyton floccosum.
Last reviewed on RxList: 12/29/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Ertaczo Information
Ertaczo - User Reviews
Ertaczo User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Here is a collection of user reviews for the medication Ertaczo sorted by most helpful.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
